Arun Azad, MBBS, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne, and chair of the ANZUP Cancer Trials Group Translational, discusses ongoing studies of lutetium-177-PSMA (177Lu-PSMA-617) radionuclide in patients with prostate cancer.
There’s the UpFrontPSMA trial (NCT04343885), a randomized phase 2 study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel alone in patients with metastatic hormone-naïve prostate cancer that is recruiting right now. Another is the LuTectomy study (NCT04430192) looking at 177Lu-PSMA-617 in patients with high-risk localized prostate cancer as presurgical treatment, a proof-of-concept phase 1/2 trial investigating whether patients can receive high doses of radiation to the prostate before surgery, according to Azad. The ENZA-p trial (NCT04419402) is currently looking at first-line enzalutamide (Xtandi) with or without 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (CRPC). An international phase 3 trial called VISION is looking at second-line 177Lu-PSMA-617 versus docetaxel in those with CRPC who previously progressed on abiraterone (Zytiga) or enzalutamide.
Azad says that 177Lu-PSMA-617 has shown efficacy in metastatic CRPC in late-stage disease, and there are more data coming out in that area. The previously mentioned studies will also show if there is efficacy in the frontline setting with 177Lu-PSMA-617 for these patients. He is excited to see these study results over the next 3 to 4 years.